<DOC>
	<DOCNO>NCT00518869</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety PG2 complementary treatment conventional chemotherapy among NSCLC patient . In reference previous study , `` Clinical Benefit Response '' `` Incidence Grade III plus VI Neutropenia '' use primary endpoint study . Clinical Benefit Response metric measurement include change cancer cancer treatment relate `` fatigue '' relate chronic fatigue syndrome ( CFS ) , change karnofsky performance status change weight . The secondary endpoint include patient 's global quality life , blood c-reactive protein level related weight change , tumor response , survival time , incidence myelosuppression ( include neutropenia , anemia thrombocytopenia ) relate G-CSF antibiotic consumption .</brief_summary>
	<brief_title>Complementary Treatment PG2 Improve Clinical Benefit Response Quality Life Fatigue</brief_title>
	<detailed_description>This multi-center , double-blind , randomize placebo-controlled study evaluate complementary effect PG2 patient advance non-small-cell lung cancer conventional chemotherapy . Patients Stage IIIb-IV non-small-cell lung cancer screen inclusion exclusion criterion eligible patient enrol study . All enrol patient randomize PG2 Placebo arm receive cisplatin-based chemotherapy treatment ( Cisplatin 75mg/m2 Docetaxel 60mg/m2 Day1 ) first three 21-day chemo-cycles . Chemo regimen modification allowable , usual , case disease progression unacceptable toxicity ( see Section 6 ) . After randomization , patient administer PG2 placebo 4 day 1st week , 3 day 2nd week 3 day 3rd week chemo-cycle 3 cycle ( Dosing Schedule Section 6 ) . Total 10 dos give cycle .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Signed informed consent form . 18 ~ 75 year old Locally advanced metastatic inoperable stage IIIbIV nonsmallcell lung cancer . Chemo/Radio naive patient Karnofsky Performance Scores ≧ 70 . Adequate bone marrow reserve . Adequate liver function . Adequate renal function . Women childbearing potential willing take contraception measure whole treatment course . Life expectancy ≧ 3 month Patient must willing able complete quality life questionnaire . Female patient pregnant breastfeed Patients brain metastasis , stroke major psychiatric disease . Patients uncontrolled systemic disease active infection , severe heart disease , uncontrollable hypertension diabetes mellitus . Patients enrol yet complete investigational drug trial within 30 day randomization .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Complementary Alternative Medicine ( CAM )</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Myelosuppression</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Fatigue</keyword>
	<keyword>EORTC QLQ-C30 LC13</keyword>
</DOC>